This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. TNX-901 is a molecularly engineered human IgG1 antibody developed by Tanox, Inc. that contains the complementarity determining regions (CDRs) of the TES-C21 murine MAb that binds specifically to human IgE. The strategy of this approach is to decrease the concentration of circulating free IgE in atopic patients using a unique monoclonal antibody (MAb) that specifically binds IgE. Tanox, Inc. and its collaborative partners, Genentech, Inc. and Novartis Pharma, have elected to terminate the study being conducted in accord with Protocol TNX-901.02 (last dose to have been administered on or before June 30, 2004). The corporate partnership has offered to provide TNX-901 to investigators from the multicenter study who wish to continue to administer study drug to those patients participating in study TNX-901.02 as of June 30, 2004. The study described in this protocol allows for continued provision of TNX-901 to those patients who continued to participate in Study TNX-901.02 until its termination. At that point, all patients were receiving a dose of 450 mg administered subcutaneously every 4 weeks.
Showing the most recent 10 out of 869 publications
